147 related articles for article (PubMed ID: 25675162)
1. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
2. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
[TBL] [Abstract][Full Text] [Related]
3. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
[TBL] [Abstract][Full Text] [Related]
6. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma: Erratum.
Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):655. PubMed ID: 37922051
[No Abstract] [Full Text] [Related]
7. Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo.
Olesen UH; Pedersen KK; Togsverd-Bo K; Biskup E; Nielsen AL; Jackerott M; Clergeaud G; Andresen TL; Haedersdal M
Lasers Surg Med; 2024 Mar; 56(3):239-248. PubMed ID: 38311811
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
Ruiz-Salas V; Podlipnik S; Sandoval-Clavijo A; Sanmartin-Jiménez O; Bernia-Petit E; Bonfill-Ortí M; Bassas-Freixas P; Yebenes-Marsal M; Flórez-Menéndez Á; Solá-Ortigosa J; Just-Sarobé M; Aguayo-Ortiz R; Masferrer I Niubó E; Quintana-Codina M; Deza G; Jaka A; Fuentes MJ; Cañueto J; Toll A
Dermatology; 2023; 239(5):685-693. PubMed ID: 37257423
[TBL] [Abstract][Full Text] [Related]
9. Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib.
Pirruccello J; Afzal MZ; Voudouri M; Shirai K
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37451798
[TBL] [Abstract][Full Text] [Related]
10. Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.
Scotti B; Melotti B; Baraldi C; Comito F; Venturi F; Lambertini M; Dika E
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e339-e341. PubMed ID: 37909360
[No Abstract] [Full Text] [Related]
11. Vismodegib treatment for recurrent basal cell carcinoma - a successful case report.
Lé AM; Nogueira M; Araújo A; Horta M
Eur J Dermatol; 2023 Jun; 33(3):332-333. PubMed ID: 37594358
[No Abstract] [Full Text] [Related]
12. Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.
Wescott R; Samlowski W
Curr Oncol; 2023 Oct; 30(10):9156-9167. PubMed ID: 37887561
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.
Jabbehdari S; Veluvolu M; Kornhauser T; Jennings TA; Pemberton JD
Ann Transl Med; 2024 Jun; 12(3):54. PubMed ID: 38911557
[TBL] [Abstract][Full Text] [Related]
14. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers.
Ravipati A; Pradeep T; Nouri K
J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N; Guerreschi P; Basset-Seguin N; Saiag P; Dupuy A; Dalac-Rat S; Dziwniel V; Depoortère C; Duhamel A; Mortier L
EClinicalMedicine; 2021 May; 35():100844. PubMed ID: 33997740
[TBL] [Abstract][Full Text] [Related]
16. Robotic assisted orbital surgery for resection of advanced periocular tumours - a case series report on the feasibility, safety and outcome.
Malik M; Daniel C; Faulkner J; Uddin J; Arora A; Jeannon JP
Eye (Lond); 2024 Jun; 38(8):1496-1501. PubMed ID: 38388832
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary Approach to Treatment of Advanced Basal Cell Carcinoma With Involvement of the Left Orbit.
Aguwa CJ; Brown R; Falcone M; Scarola DE; Hegde UP; Perez MI
J Drugs Dermatol; 2024 Jun; 23(6):e142-e143. PubMed ID: 38834208
[No Abstract] [Full Text] [Related]
18. A 5-year review of 1220 malignant periocular tumours in an English county.
Lin Z; Sheikh U; Igali L; Hemmant B
Eye (Lond); 2023 Apr; 37(6):1271-1274. PubMed ID: 35614342
[TBL] [Abstract][Full Text] [Related]
19. Personalized treatment concepts in extraocular cancer.
Ju S; Rokohl AC; Guo Y; Yao K; Fan W; Heindl LM
Adv Ophthalmol Pract Res; 2024; 4(2):69-77. PubMed ID: 38590555
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.
Yin VT; Merritt H; Esmaeli B
World J Clin Cases; 2014 Sep; 2(9):432-8. PubMed ID: 25232546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
